~~<i id='C4FDC02D56'><strike id='C4FDC02D56'><tt id='C4FDC02D56'><pre id='C4FDC02D56'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

knowledge

author：hotspot 2025-09-03 03:18:16 - browse：532

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Arc Institute generative AI designs new CRISPR systems

focus

leisure time

focus

knowledge

focus

BobKocher,apartneratventurecapitalfirmVenrock,speakingatSTAT'sBreakthroughSummitinSanFrancisco.Sarah

WSS

All of Us, NIH's precision medicine initiative, gets a big boost

Infant mortality in U.S. rose last year for first time in decades: CDC

Solving academic medical centers' existential crisis

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Brain injuries and the importance of a second opinion

How to convince healthy people to buy insurance

entertainment

knowledge

focus

Jerome Adams on the need for new antivirals for Covid

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Hepatitis C has a cure — but many Americans still lack access to it

Brain injuries and the importance of a second opinion

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Brain injuries and the importance of a second opinion

Sports medicine is finally prioritizing gender equality

Gene therapy’s promise and the high cost of hope

Walensky prepares to leave CDC — and Congress — behind

Lung cancer screening guidelines updated for cigarette smokers

leisure time

Second House panel advances two

Medicare proceeds with plan to claw back hospital funds

It's time to retire 'poor historian' from clinicians' vocabularies

Helping hospitals and community health centers plan for resilience

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Inari Medical to buy amputation prevention company LimFlow

focus

knowledge

knowledge

focus